

8<sup>th</sup> September, 2021

To,  
The Corporate Relationship Department,  
**BSE Limited**,  
Phiroze Jeejeebhoy Towers,  
Dalal Street,  
Mumbai - 400001.  
Scrip Code: 540737

Dear Sir(s)/Ma'am,

**Sub: Acquisition of 100% equity stake of Akshar Jyot Private Limited**  
**Ref: Disclosure pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.**

In continuation of our earlier intimation dated 7<sup>th</sup> September, 2021, we are pleased to inform that the Company has acquired the 100% equity stake of Akshar Jyot Private Limited ("AJPL"), which is in process to acquire 26% equity stake in Dhari Chemicals Limited ("DCL").

The required disclosure pursuant to Regulation 30 of SEBI (LODR) Regulations 2015 as per SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 9, 2015 is enclosed herewith.

You are requested to take the same on your record.

Thanking you,

Yours faithfully,

**For Shree Ganesh Remedies Limited**

**Chandulal Manubhai Kothia**  
**Managing Director**  
**DIN: 00652806**



**Head Office (Unit-1) :**  
Plot No. 6011-12, GIDC Estate,  
Anklekshwar - 393 002, Gujarat (INDIA)  
Ph.: +91 9614961469, 7574976076  
**CIN No. : L24230GJ1995PLC025661**

**(Unit-2) :**  
Plot No. 6714/2,-6715 GIDC Estate,  
Anklekshwar - 393 002, Gujarat (INDIA)  
Ph.: +91 9614961469, 7574976076  
**GSTIN : 24ABACS1471R1Z0 (Zero)**



www.ganeshremedies.com  
WEBSITE  
contact@ganeshremedies.com |  
EMAIL

Sr No.	Particulars	Details				
a)	Name of the target entity, details in brief such as size, turnover etc.	<p>AJPL was incorporated to carry on the business of manufacturing of pharmaceuticals intermediates, medicinal preparations and its related articles and products.</p> <p>Authorised Capital (Rs) 1,00,000 Paid up Capital (Rs) 1,00,000</p>				
b)	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length".	No				
c)	Industry to which the entity being acquired belongs.	Pharmaceuticals Intermediates				
d)	Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity).	This acquisition is in furtherance of our earlier intimation dated 7 <sup>th</sup> September, 2021.				
e)	Brief details of any governmental or regulatory approvals required for the acquisition.	No approvals are required from any governmental or regulatory authorities.				
f)	Indicative time period for completion of the acquisition.	Completed.				
g)	Nature of consideration - whether cash consideration or share swap and details of the same.	The transaction is completed by way of a cash transaction with the existing shareholders of AJPL				
h)	Cost of acquisition or the price at which the shares are acquired.	The Company has acquired 100% equity stake in AJPL on the basis of Book Value / Net Asset Value arrived in the valuation report i.e., for Rs. 100,000/-				
i)	Percentage of shareholding / control acquired and / or number of shares acquired.	<table border="1"> <thead> <tr> <th data-bbox="778 1574 1177 1630">Particulars of shares acquired</th> <th data-bbox="1185 1574 1460 1630">% of Holding</th> </tr> </thead> <tbody> <tr> <td data-bbox="778 1641 1177 1664">10,000 Equity Shares</td> <td data-bbox="1185 1641 1460 1664">100%</td> </tr> </tbody> </table>	Particulars of shares acquired	% of Holding	10,000 Equity Shares	100%
Particulars of shares acquired	% of Holding					
10,000 Equity Shares	100%					
j)	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief).	AJPL was incorporated to carry on the business of manufacturing of pharmaceuticals intermediates, medicinal preparations and its related articles and products.				

*Cell -*

